Tang Capital Management LLC Raises Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Tang Capital Management LLC grew its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 16.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,429,500 shares of the biotechnology company's stock after purchasing an additional 1,200,000 shares during the period. Aurinia Pharmaceuticals makes up approximately 5.0% of Tang Capital Management LLC's investment portfolio, making the stock its 2nd largest holding. Tang Capital Management LLC owned 5.89% of Aurinia Pharmaceuticals worth $75,697,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AUPH. SBI Securities Co. Ltd. acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $25,000. Tower Research Capital LLC TRC increased its stake in shares of Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 2,635 shares during the last quarter. Natixis purchased a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter worth about $49,000. Blue Trust Inc. raised its position in Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock valued at $57,000 after acquiring an additional 6,174 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at $90,000. 36.83% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Stock Performance

NASDAQ AUPH traded up $0.04 during midday trading on Wednesday, hitting $8.34. The company had a trading volume of 1,115,653 shares, compared to its average volume of 1,324,194. The firm has a fifty day simple moving average of $8.02 and a two-hundred day simple moving average of $8.26. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -55.60 and a beta of 1.16. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $5.11 and a fifty-two week high of $10.67.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.08. The business had revenue of $62.47 million during the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%. Equities analysts forecast that Aurinia Pharmaceuticals Inc. will post 0.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Aurinia Pharmaceuticals news, insider Greg Keenan sold 8,305 shares of the company's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $8.23, for a total transaction of $68,350.15. Following the sale, the insider now directly owns 153,484 shares of the company's stock, valued at approximately $1,263,173.32. This represents a 5.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Matthew Maxwell Donley sold 65,902 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $527,216.00. Following the completion of the transaction, the chief operating officer now owns 739,456 shares of the company's stock, valued at $5,915,648. This trade represents a 8.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold 343,898 shares of company stock valued at $2,753,094 over the last quarter. Corporate insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, March 27th.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.